{
    "clinical_study": {
        "@rank": "55493", 
        "arm_group": [
            {
                "arm_group_label": "12.5 mg empagliflozin/850 mg metformin", 
                "arm_group_type": "Experimental", 
                "description": "24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/850 mg metformin", 
                "arm_group_type": "Experimental", 
                "description": "24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/500 mg metformin", 
                "arm_group_type": "Experimental", 
                "description": "24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/500 mg metformin", 
                "arm_group_type": "Experimental", 
                "description": "24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the trial is to assess the relative bioavailability of fixed dose combination\n      tablets of  Empagliflozin and metformin compared to the administration of single tablets\n      (Empagliflozin  and metformin ) in Chinese subjects. The availability of a fixed dose\n      combination tablet is expected to significantly enhance patient's compliance with\n      antidiabetic treatment, in particular with concern to the frequent polypharmacy in diabetic\n      patients."
        }, 
        "brief_title": "Bioavailability of Empagliflozin/Metformin Fixed Dose Combination(FDC) in Healthy Chinese Volunteers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Healthy male and female subjects\n\n        Exclusion criteria:\n\n        Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102932", 
            "org_study_id": "1276.23"
        }, 
        "intervention": [
            {
                "arm_group_label": "5 mg empagliflozin/850 mg metformin", 
                "description": "5 mg empagliflozin/850 mg metformin FDC", 
                "intervention_name": "5 mg empagliflozin/850 mg metformin FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/500 mg metformin", 
                "description": "10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet", 
                "intervention_name": "12.5 mg empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/850 mg metformin", 
                "description": "10mg empagliflozin tablet and 2.5 mg empagliflozin tablet", 
                "intervention_name": "12.5 mg empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/850 mg metformin", 
                "description": "850mg metformin tablet", 
                "intervention_name": "850 mg metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/850 mg metformin", 
                "description": "5 mg empagliflozin", 
                "intervention_name": "5 mg empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/500 mg metformin", 
                "description": "5 mg empagliflozin", 
                "intervention_name": "5 mg empagliflozin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/850 mg metformin", 
                "description": "850 mg metformin", 
                "intervention_name": "850 mg metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/850 mg metformin", 
                "description": "12.5 mg empagliflozin/850 mg metformin FDC", 
                "intervention_name": "12.5 mg empagliflozin/850 mg metformin FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/500 mg metformin", 
                "description": "12.5 mg empagliflozin/500 mg metformin FDC", 
                "intervention_name": "12.5 mg empagliflozin/500 mg metformin FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/500 mg metformin", 
                "description": "5 mg empagliflozin/500 mg metformin FDC", 
                "intervention_name": "5 mg empagliflozin/500 mg metformin FDC", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "12.5 mg empagliflozin/500 mg metformin", 
                "description": "500 mg metformin", 
                "intervention_name": "500 mg metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "5 mg empagliflozin/500 mg metformin", 
                "description": "500 mg metformin", 
                "intervention_name": "500 mg metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "1276.23.86002 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, Two-way Crossover Study", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102932"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "collaborator": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}